London · Delayed Price · Currency is GBP · Price in GBX PureTech Health Statistics
Total Valuation
PureTech Health has a market cap or net worth of GBP 289.18 million. The enterprise value is 220.93 million.
| Market Cap | 289.18M |
| Enterprise Value | 220.93M |
Important Dates
The next estimated earnings date is Friday, August 28, 2026.
| Earnings Date | Aug 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
PureTech Health has 243.42 million shares outstanding. The number of shares has decreased by -5.37% in one year.
| Current Share Class | 243.42M |
| Shares Outstanding | 243.42M |
| Shares Change (YoY) | -5.37% |
| Shares Change (QoQ) | +0.69% |
| Owned by Insiders (%) | 3.88% |
| Owned by Institutions (%) | 71.13% |
| Float | 156.80M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 83.54 |
| PB Ratio | 1.27 |
| P/TBV Ratio | 1.25 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 63.82 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.59, with a Debt / Equity ratio of 0.66.
| Current Ratio | 6.59 |
| Quick Ratio | 6.41 |
| Debt / Equity | 0.66 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.39 |
| Interest Coverage | -2.15 |
Financial Efficiency
Return on equity (ROE) is -30.85% and return on invested capital (ROIC) is -44.69%.
| Return on Equity (ROE) | -30.85% |
| Return on Assets (ROA) | -10.82% |
| Return on Invested Capital (ROIC) | -44.69% |
| Return on Capital Employed (ROCE) | -20.15% |
| Weighted Average Cost of Capital (WACC) | 11.68% |
| Revenue Per Employee | 38,463 |
| Profits Per Employee | -905,956 |
| Employee Count | 90 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -625,606 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -11.21% in the last 52 weeks. The beta is 0.77, so PureTech Health's price volatility has been lower than the market average.
| Beta (5Y) | 0.77 |
| 52-Week Price Change | -11.21% |
| 50-Day Moving Average | 124.45 |
| 200-Day Moving Average | 125.92 |
| Relative Strength Index (RSI) | 44.76 |
| Average Volume (20 Days) | 688,638 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PureTech Health had revenue of GBP 3.46 million and -81.54 million in losses. Loss per share was -0.34.
| Revenue | 3.46M |
| Gross Profit | -38.48M |
| Operating Income | -73.12M |
| Pretax Income | -82.42M |
| Net Income | -81.54M |
| EBITDA | -71.94M |
| EBIT | -73.12M |
| Loss Per Share | -0.34 |
Balance Sheet
The company has 214.52 million in cash and 151.02 million in debt, with a net cash position of 63.50 million or 0.26 per share.
| Cash & Cash Equivalents | 214.52M |
| Total Debt | 151.02M |
| Net Cash | 63.50M |
| Net Cash Per Share | 0.26 |
| Equity (Book Value) | 227.12M |
| Book Value Per Share | 0.96 |
| Working Capital | 192.22M |
Cash Flow
In the last 12 months, operating cash flow was -63.25 million and capital expenditures -4,458, giving a free cash flow of -63.26 million.
| Operating Cash Flow | -63.25M |
| Capital Expenditures | -4,458 |
| Depreciation & Amortization | 1.17M |
| Net Borrowing | -2.65M |
| Free Cash Flow | -63.26M |
| FCF Per Share | -0.26 |
Margins
| Gross Margin | n/a |
| Operating Margin | -2,112.34% |
| Pretax Margin | -2,380.90% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
PureTech Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 5.37% |
| Shareholder Yield | 5.37% |
| Earnings Yield | -28.20% |
| FCF Yield | -21.87% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for PureTech Health is 359.40, which is 203.36% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 359.40 |
| Price Target Difference | 203.36% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 96.50% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PureTech Health has an Altman Z-Score of 0.88 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.88 |
| Piotroski F-Score | 3 |